Ohio Clinical Trials Report — March 2026

Ohio residents have a strictly limited window to participate in several major medical research initiatives before they permanently close to new participants. Within the next ninety days, 206 clinical trials across the state will finalize their enrollment phases. Time is running out for patients seeking experimental therapies, as well as for residents without underlying conditions. Currently, 22 of these soon-to-close studies are actively seeking healthy volunteers to establish baseline medical data. Patients managing specific chronic and acute diagnoses face immediate deadlines to join research programs focused on the following conditions:

• Prostate cancer
• Multiple myeloma
• Obesity
• Breast cancer
• Cystic fibrosis
• Type 2 diabetes mellitus
• Chronic spontaneous urticaria
• Focal segmental glomerulosclerosis
• Bladder cancer
• Cardiovascular diseases

Major Phase 3 Launches and Massive Biobanks

Despite the wave of impending closures, March brings a fresh influx of high-capacity research projects to the state. Major pharmaceutical sponsors and leading academic institutions are launching massive Phase 3 drug trials and comprehensive biobank registries. ModernaTX, Inc. is recruiting thousands of healthy adults for a late-stage pandemic influenza vaccine trial, while Hoffmann-La Roche is developing a novel blood-based diagnostic test for traumatic brain injuries. In the academic sector, Children's Hospital Medical Center in Cincinnati is undertaking two enormous biorepository projects aimed at redefining congenital and pediatric heart disease research.

• ModernaTX, Inc. is seeking four thousand healthy adults for a Phase 3 trial (NCT07496450) to evaluate the safety, reactogenicity, and humoral immunogenicity of two doses of the mRNA-1018-H5 pandemic influenza vaccine.
• Children's Hospital Medical Center, Cincinnati is launching a massive registry (NCT07477197) requiring five thousand participants to collect biospecimens from adults with congenital heart disease to study biologic mechanisms of deterioration.
• A parallel pediatric biorepository (NCT07478354) sponsored by Children's Hospital Medical Center, Cincinnati also seeks five thousand participants to facilitate basic and translational research in pediatric heart disease.
• Hoffmann-La Roche requires two thousand participants to develop a blood-based biomarker test (NCT07455136) that aids in the diagnosis and prognosis of traumatic brain injuries in adults.
• Revolution Medicines, Inc. is enrolling nine hundred patients in a Phase 3 study (NCT07491445) evaluating Daraxonrasib as a first-line treatment for metastatic pancreatic adenocarcinoma.
• Boehringer Ingelheim is conducting the Phase 3 DAREON-Lung-1 trial (NCT07472517) with six hundred seventy participants to compare Obrixtamig plus standard treatment against standard chemotherapy alone for advanced small cell lung cancer.
• Axsome Therapeutics, Inc. is recruiting five hundred eight patients for a Phase 3 randomized withdrawal trial (NCT07484217) assessing Solriamfetol in treating major depressive disorder accompanied by excessive daytime sleepiness.
• MetroHealth Medical Center is launching the ISAAC study (NCT07447284) to test behavioral interventions and peer support on continuous positive airway pressure adherence among four hundred forty African American couples.

Geographic Distribution and Intervention Types

The clinical research infrastructure remains highly active throughout the state, with 3,118 clinical trials currently recruiting across one hundred fifty-one Ohio cities and over one thousand seven hundred individual research sites. The pace of new study launches has stabilized, with 50 new trials opening this month compared to sixty-one at the start of the year. Pharmaceutical interventions dominate the new landscape with sixteen drug trials, followed by medical device evaluations, behavioral studies, procedural research, and biological testing.

Geographically, new research opportunities are heavily clustered in the state's three largest metropolitan areas. Columbus leads the state with sixteen newly opened trials, while Cincinnati and Cleveland follow closely with thirteen each. Residents living outside these primary hubs still have access to cutting-edge medical research, as new trials have opened their doors this month in several other municipalities:

• Maumee
• Westlake
• Beachwood
• Youngstown
• Dayton
• Strongsville
• Athens

Targeted Diagnoses and Broad Eligibility

March's new clinical trials target a diverse array of chronic and acute conditions. Researchers are actively seeking patients managing traumatic brain injuries, platinum-resistant ovarian cancer, endometrial cancer, ALK-positive non-small cell lung cancer, and autosomal dominant polycystic kidney disease. The sponsorship of these trials heavily favors academic and regional medical centers, with thirty-three studies funded by institutions like Ohio State University, the University of Cincinnati, and The Cleveland Clinic, compared to seventeen driven by industry partners.

Eligibility criteria for these new studies ensure that diverse demographic groups can participate in scientific advancement. Older adults have extensive options, with 37 of the new trials specifically designing their protocols to include senior populations. Pediatric research is also expanding, as twelve new studies are open to children and adolescents. Highly targeted demographic research includes two trials exclusively for female participants.

For those without a specific medical diagnosis, twelve of this month's new trials are actively welcoming healthy volunteers. This brings the total number of open, recruiting trials for healthy participants across Ohio to 300, offering ample opportunity for the general public to contribute to medical science.

As the spring research season accelerates, Ohio's clinical trial ecosystem is preparing to process the massive influx of biospecimens and patient data generated by this month's high-capacity registries, setting the foundation for the next generation of targeted cardiovascular and oncological therapies.